MeiraGTx Holdings plc (NASDAQ: MGTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 16.83 | EPS (ttm) | -2.04 | Insider Own | 25.36% | Shs Outstand | 92.61M | Perf Week | 3.60% |
| Market Cap | 1.27B | Forward P/E | - | EPS next Y | -1.71 | Insider Trans | -1.50% | Shs Float | 70.14M | Perf Month | -11.49% |
| Enterprise Value | 1.19B | PEG | 0.45 | EPS next Q | -0.46 | Inst Own | - | Short Float | 5.31% | Perf Quarter | 17.05% |
| Income | -157.00M | P/S | 32.29 | EPS this Y | 115.34% | Inst Trans | - | Short Ratio | 4.44 | Perf Half Y | 80.27% |
| Sales | 38.00M | P/B | 5.68 | EPS next Y | -647.63% | ROA | 19.92% | Short Interest | 3.72M | Perf YTD | 66.67% |
| Book/sh | 2.33 | P/C | 8.58 | EPS next 5Y | 37.45% | ROE | 284.38% | 52W High | 15.35 -13.68% | Perf Year | 80.76% |
| Cash/sh | 1.54 | P/FCF | 187.74 | EPS past 3/5Y | - | ROIC | 52.45% | 52W Low | 6.62 100.15% | Perf 3Y | 124.58% |
| Dividend Est. | - | EV/EBITDA | 4.44 | Sales past 3/5Y | 71.71% 38.32% | Gross Margin | 97.19% | Volatility | 3.14% 4.13% | Perf 5Y | 10.14% |
| Dividend TTM | - | EV/Sales | 31.42 | EPS Y/Y TTM | 3.77% | Oper. Margin | 46.30% | ATR (14) | 0.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.76 | Sales Y/Y TTM | 15.15% | Profit Margin | 19.87% | RSI (14) | 48.81 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.76 | EPS Q/Q | 456.25% | SMA20 | -3.16% | Beta | 1.31 | Target Price | 26.00 |
| Payout | 0.00% | Debt/Eq | 1.19 | Sales Q/Q | 7925.00% | SMA50 | 1.24% | Rel Volume | 1.13 | Prev Close | 13.05 |
| Employees | 393 | LT Debt/Eq | -10.17 | Earnings | Nov 12 | SMA200 | 33.10% | Avg Volume | 830.15K | Price | 13.25 |
| IPO Date | Jun 08, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 473.09% 45819.14% | Net Debt/EBITDA | -0.12 | Volume | 941,198 | Change | 1.53% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-08-26 | Reiterated | RBC Capital | Outperform | $24 → $26 |
| Apr-17-26 | Reiterated | RBC Capital | Outperform | $16 → $24 |
| Mar-27-26 | Reiterated | Piper Sandler | Overweight | $26 |
| Nov-24-25 | Initiated | H.C | Buy | $20 |
| Nov-14-25 | Reiterated | RBC Capital | Outperform | $9.00 → $16 |
| Aug-13-24 | Reiterated | RBC Capital | Outperform | $9.00 |
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 38 | 81 | 33 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 28 | 5 | 24 | — | — | — | — | — | — | |
| Gross Profit | 11 | 77 | 9 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 54 | 53 | 54 | — | — | — | — | — | — | |
| Research and Development | 116 | 130 | 119 | — | — | — | — | — | — | |
| Other Operating Expense | -2 | 0 | 1 | — | — | — | — | — | — | |
| Operating Income | -158 | -106 | -164 | — | — | — | — | — | — | |
| Interest Expense | 12 | 12 | 13 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 4 | 30 | — | — | — | — | — | — | |
| Net Income Before Taxes | -157 | -114 | -148 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -157 | -114 | -148 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -157 | -114 | -148 | — | — | — | — | — | — | |
| Net Income | -157 | -114 | -148 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.04 | -1.42 | -2.12 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.04 | -1.42 | -2.12 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.04 | -1.42 | -2.12 | — | — | — | — | — | — | |
| EBITDA | -133 | -89 | -122 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 28.24 | 7.85 | 12.92 | — | — | — | — | — | — | |
| Gross Margin | 28.95 | 95.06 | 27.27 | — | — | — | — | — | — | |
| Operating Margin | -415.79 | -130.86 | -496.97 | — | — | — | — | — | — | |
| Net Margin | -413.16 | -140.74 | -448.48 | — | — | — | — | — | — | |
| Shares Outstanding | 81 | 80 | 70 | — | — | — | — | — | — | |
| Market Capitalization | 1,073 | 636 | 426 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Forbes Alexandria | PRESIDENT & CEO | Aug 18 '26 | Sale | 13.86 | 62,000 | 859,320 | 1,325,695 | Aug 18 |
| Giroux Richard | CFO & COO | Jul 21 '26 | Sale | 12.51 | 56,000 | 700,560 | 908,530 | Jul 21 |
| Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY | Jul 07 '26 | Sale | 14.80 | 27,659 | 409,470 | 640,846 | Jul 07 |
| Harris Keith R. | Director | Jun 10 '26 | Option Exercise | 0.00 | 75,000 | 0 | 200,000 | Jun 10 |
| Forbes Alexandria | PRESIDENT & CEO | May 19 '26 | Sale | 9.17 | 62,000 | 568,540 | 1,387,695 | May 19 |
| Giroux Richard | CFO & COO | Apr 21 '26 | Sale | 10.22 | 56,000 | 572,320 | 971,530 | Apr 21 |
| Naylor Stuart | CHIEF DEV. OFFICER | Apr 07 '26 | Sale | 9.36 | 27,661 | 258,907 | 668,505 | Apr 07 |
| Forbes Alexandria | PRESIDENT & CEO | Mar 24 '26 | Sale | 7.41 | 62,000 | 459,420 | 1,449,695 | Mar 24 |
| Zeldin Robert K | CHIEF MEDICAL OFFICER | Feb 21 '26 | Option Exercise | 0.00 | 7,500 | 0 | 175,840 | Feb 23 |
| Wollin Robert J | GENERAL COUNSEL AND SECRETARY | Feb 21 '26 | Option Exercise | 0.00 | 11,250 | 0 | 63,326 | Feb 23 |
| Naylor Stuart | CHIEF DEV. OFFICER | Feb 21 '26 | Option Exercise | 0.00 | 25,000 | 0 | 707,916 | Feb 23 |
| Giroux Richard | CFO & COO | Feb 21 '26 | Option Exercise | 0.00 | 60,000 | 0 | 1,059,256 | Feb 23 |
| Forbes Alexandria | PRESIDENT & CEO | Feb 21 '26 | Option Exercise | 0.00 | 62,500 | 0 | 1,544,743 | Feb 23 |
| Zeldin Robert K | CHIEF MEDICAL OFFICER | Jan 17 '26 | Option Exercise | 0.00 | 35,000 | 0 | 182,291 | Jan 21 |
| Wollin Robert J | GENERAL COUNSEL AND SECRETARY | Jan 17 '26 | Option Exercise | 0.00 | 50,000 | 0 | 79,282 | Jan 21 |